CTLA4 and type 1 diabetes mellitus: Disruption of B cell/T cell interaction through abatacept treatment (CTLA4-Ig) delayed beta cell decline in new-onset T1D individuals,12 while non-responders showed increased B cell frequencies and elevated B cell genes, supporting a role for B cell help in human T1D.13